Patents Assigned to VAXINNATE CORPORATION
-
Patent number: 9446115Abstract: Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject.Type: GrantFiled: December 1, 2015Date of Patent: September 20, 2016Assignee: VaxInnate CorporationInventors: Thomas J. Powell, Valerian Nakaar, Langzhou Song, James W. Huleatt, William F. McDonald, Duane D. Hewitt
-
Patent number: 9234009Abstract: Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject.Type: GrantFiled: September 23, 2014Date of Patent: January 12, 2016Assignee: VaxInnate CorporationInventors: Thomas J. Powell, Valerian Nakaar, Langzhou Song, James W. Huleatt, William F. McDonald, Duane D. Hewitt
-
Patent number: 9211320Abstract: Compositions that include at least a portion of a flagellin and an antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to infection.Type: GrantFiled: December 17, 2014Date of Patent: December 15, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
-
Patent number: 9205138Abstract: Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one viral antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection.Type: GrantFiled: December 16, 2014Date of Patent: December 8, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
-
Patent number: 9200042Abstract: Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion.Type: GrantFiled: December 10, 2014Date of Patent: December 1, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
-
Patent number: 9056901Abstract: Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion. The protein portion includes at least a portion of a globular head, and at least a portion of at least one secondary structure having at least one ?-sheet at a bottom of the globular head that causes the globular head to essentially retain its tertiary structure. The protein portion made by the methods of the invention lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. A nucleic acid sequence encoding the protein portion is transformed into a prokaryotic host cell.Type: GrantFiled: February 7, 2013Date of Patent: June 16, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
-
Patent number: 8945579Abstract: Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. Compositions administered to the subject can further include a carrier and can be administered in single or multiple doses.Type: GrantFiled: February 6, 2013Date of Patent: February 3, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
-
Patent number: 8932605Abstract: Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one viral antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection.Type: GrantFiled: October 15, 2010Date of Patent: January 13, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
-
Patent number: 8932598Abstract: Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin.Type: GrantFiled: June 28, 2013Date of Patent: January 13, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
-
Patent number: 8871221Abstract: Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject.Type: GrantFiled: October 10, 2013Date of Patent: October 28, 2014Assignee: Vaxinnate CorporationInventors: Thomas J. Powell, Valerian Nakaar, Langzhou Song, James W. Huleatt, William F. McDonald, Duane D. Hewitt
-
Publication number: 20140255438Abstract: Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin.Type: ApplicationFiled: June 28, 2013Publication date: September 11, 2014Applicant: VaxInnate CorporationInventors: Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
-
Publication number: 20140235836Abstract: The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity and/or improve folding of the protein.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: VaxInnate CorporationInventors: Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
-
Publication number: 20140065177Abstract: Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin.Type: ApplicationFiled: June 28, 2013Publication date: March 6, 2014Applicant: VaxInnate CorporationInventors: Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
-
Publication number: 20140037683Abstract: Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Applicant: VAXINNATE CORPORATIONInventors: Thomas J. Powell, Valerian Nakaar, Langzhou Song, James W. Huleatt, William F. McDonald, Duane D. Hewitt
-
Publication number: 20130330367Abstract: The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity. The present invention also relates to methods of evaluating the vaccines by measuring the relative expression of certain gene markers. Altered expression of the genes relative to flagellin control sample may indicate that the vaccine is suitable to stimulate an adaptive immune response to the antigen component in the subject with minimal side effects.Type: ApplicationFiled: August 20, 2013Publication date: December 12, 2013Applicant: Vaxinnate CorporationInventors: Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
-
Publication number: 20130224798Abstract: Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion. The protein portion includes at least a portion of a globular head, and at least a portion of at least one secondary structure having at least one ?-sheet at a bottom of the globular head that causes the globular head to essentially retain its tertiary structure. The protein portion made by the methods of the invention lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. A nucleic acid sequence encoding the protein portion is transformed into a prokaryotic host cell.Type: ApplicationFiled: February 7, 2013Publication date: August 29, 2013Applicant: VAXINNATE CORPORATIONInventor: VAXINNATE CORPORATION
-
Publication number: 20130136763Abstract: Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. Compositions administered to the subject can further include a carrier and can be administered in single or multiple doses.Type: ApplicationFiled: February 6, 2013Publication date: May 30, 2013Applicant: VAXINNATE CORPORATIONInventor: Vaxlnnate Corportion
-
Publication number: 20130095130Abstract: Compositions that include a flagellin/antigen protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen and methods of administering these compositions to humans at least 49 years old. The compositions stimulate immune response to the antigen, in particular, a protective immune response to the antigen, in the human, such as an elderly human.Type: ApplicationFiled: January 5, 2011Publication date: April 18, 2013Applicant: VAXINNATE CORPORATIONInventors: David Taylor, Alan Shaw, Lynda Tussey, Robert Becker
-
Patent number: 8420102Abstract: Methods of making and compositions that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a membrane fusion domain, a transmembrane domain and a cytoplasmic domain. Compositions can further include a Toll-like Receptor agonist and a carrier protein.Type: GrantFiled: March 6, 2007Date of Patent: April 16, 2013Assignee: VaxInnate CorporationInventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
-
Publication number: 20090068224Abstract: The present invention provides novel methods to identify polypeptide ligands for Toll-like Receptors (TLRs), such as TLR2, TLR4 and TLR5. The method involves the use of phage display technology in an iterative biopanning procedure. The invention also provides polypeptide TLR ligands identified by the methods of the invention. In preferred embodiments, the polypeptide TLR ligands so identified modulate TLR signaling and thereby regulate the Innate Immune Response. The invention also provides vaccines comprising a polypeptide TLR ligand identified by the methods of the invention and an antigen. The invention also provides methods of modulating TLR signaling using the polypeptide TLR ligands and vaccines of the invention.Type: ApplicationFiled: January 26, 2006Publication date: March 12, 2009Applicant: VAXINNATE CORPORATIONInventors: Valerian Nakaar, Yan Huang, Thomas Powell